87%+
Sensitivity
Response prediction
70%+
Success Rate
Establishment
2-4
Weeks
Culture time
100%
Specificity
Non-responders
Patient-derived tumor organoids (PDTOs) retain genetic and phenotypic characteristics of original tumors. Multiple studies show PDTOs predict chemotherapy response with >87% sensitivity and near-100% specificity for identifying non-responders, enabling personalized treatment selection.
CANCER TYPES
Colorectal
Most established; high success rates; chemotherapy selection
Pancreatic
Critical need; poor prognosis; treatment optimization
Breast
Subtype modeling; endocrine therapy response
Ovarian
Platinum response; maintenance therapy selection
Lung
NSCLC; targeted therapy matching
Gastric
Chemotherapy optimization; HER2 status
KEY PROVIDERS
Biobank
Crown Bio
Indivumed acquisition; largest biobank
Platform
HUB Organoids
Clevers technology; Merck acquisition
Services
Champions Oncology
TumorGraft PDX + organoid platform